ABSTRACT The relationship of features of beryllium disease to the estimated exposure to beryllium has been investigated over a 30-year period at a factory manufacturing beryllium products. The factory opened in 1952. Of the 146 men who had worked there for more than six months up to 1963, 89% were seen at that time and were followed up in 1973. The nine who continued to work in the factory and those who were engaged subsequently were examined in 1977. On each occasion a clinical interview, occupational history, chest radiograph, and assessment of lung function were carried out. The findings of the main survey were related to the beryllium content of the dust measured by mass spectrometry for 1952-60 when over 3000 determinations were made. In no part of the plant did the estimated average daily exposure exceed 2 μg m, and only 9% of individual determinations exceeded this level. Twenty determinations exceeded 25 μg m. During the period under review, four men developed the clinical, radiographic, and physiological features of beryllium disease. Two men acquired abnormal chest radiographs consistent with beryllium disease but without other features, and one developed probable beryllium disease despite the diagnosis not being confirmed at necropsy. The affected men were all exposed to beryllium oxide or hydroxide but in a wide range of estimated doses. In six the changes developed after exposure had ceased; trigger factors including patch testing may have contributed to their illness. Seventeen men recalled episodes of brief exposure to high concentrations of dust, two developed pneumonitis from which they recovered completely, and one developed chronic beryllium disease after a further 23 years' exposure. In subjects without clinical or radiographic evidence of disease no convincing evidence was obtained for any association between the lung function and the estimated exposure to beryllium.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1009111 | PMC |
http://dx.doi.org/10.1136/oem.40.1.13 | DOI Listing |
Trop Med Infect Dis
October 2024
Armauer Hansen Research Institute, Addis Ababa P.O. Box 1005, Ethiopia.
Am J Ind Med
January 2025
Division of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
Background: Despite the utility of the beryllium lymphocyte proliferation test (BeLPT), distinguishing sarcoidosis, a disease of unknown etiology, from chronic beryllium disease (CBD), has long posed a diagnostic challenge. It is unclear if beryllium-exposed sarcoidosis cases (Be-exp-Sarc) are clinically distinct from CBD, or are misdiagnosed cases of CBD.
Methods: We performed a case-case study of 40 beryllium-exposed individuals diagnosed with Be-exp-Sarc compared to 40 frequency-matched CBD cases.
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
September 2024
School of Public Health, Guangxi Medical University, Nanning 530021, China.
Thorax
October 2024
Thoracic Surgery, SLK-Lungenklinik Lowenstein, Lowenstein, Germany.
Int J Mol Sci
July 2024
Department of Nephrology and Dialysis, Brugmann University Hospital, Université libre de Bruxelles, 1020 Bruxelles, Belgium.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!